share_log

Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target

Benzinga ·  Mar 21 10:06

Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment